Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

16.15 -0.45 (-2.71%)
Streaming Delayed Price Updated: 10:38 AM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in June Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
YL212 expands Zai Lab’s lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531) 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in March Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
From Zai Lab Limited
Via GlobeNewswire
News headline image
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
News headline image
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in February Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in January Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
News headline image
Zai Lab Launches its first Trust Report
Outlines Company’s ESG Strategy through its Trust for Life Commitments 
From Zai Lab Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.